Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-09-14, Stock:ABBV, The news for the past five days is as follows:
2018-09-07: NEWS1: Daily Dividend Report: AMT, RCL, ABBV, AMAT, NUE, KRC.NEWS2: Daily Dividend Report: AMT, RCL, ABBV, AMAT, NUE, KRC.NEWS3: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ACAD, ABBV and FB.NEWS4: Vertex Completes Enrollment in Triple Combination Studies.NEWS5: Vertex Completes Enrollment in Triple Combination Studies.NEWS6: AbbVie Declares Quarterly Dividend.NEWS7: Vertex Completes Enrollment in Triple Combination Studies.NEWS8: Lilly, Teva, Pfizer & Others Await FDA Decisions in September.NEWS9: Jim Cramer Weighs In On CarMax, AbbVie And More.
2018-09-10: NEWS1: Eli Lilly Initiates New Trial for Taltz in Plaque Psoriasis.
2018-09-11: NEWS1: Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA® (venetoclax tablets) Label.
2018-09-12: NEWS1: 5 Growth Stocks to Buy for Reliable Income in Retirement.NEWS2: 5 Growth Stocks to Buy for Reliable Income in Retirement.NEWS3: 5 Growth Stocks to Buy for Reliable Income in Retirement.NEWS4: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FIZZ, RMTI, TTPH, ABBV and GDS.NEWS5: AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia.NEWS6: AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia.NEWS7: SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline – September 24, 2018.NEWS8: AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia.
2018-09-13: NEWS1: AbbVie Rises 3.02%.NEWS2: Should Value Investors Consider AbbVie (ABBV) Stock Now?.NEWS3: Should Value Investors Consider AbbVie (ABBV) Stock Now?.NEWS4: AbbVie Inc. -- Moody's assigns Baa2 to AbbVie's sr. notes; stable outlook.NEWS5: Should Value Investors Consider AbbVie (ABBV) Stock Now?.NEWS6: AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress.NEWS7: AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis.

Answer: Decrease